Trials / Completed
CompletedNCT00192764
High Dose CHOP in Lymphoma
Phase II Study of Short High-dose CHOP Chemotherapy for Aggressive Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- Rambam Health Care Campus · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | high-dose cyclophosphamide |
Timeline
- Start date
- 1996-12-01
- Completion
- 2010-09-01
- First posted
- 2005-09-19
- Last updated
- 2010-09-22
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00192764. Inclusion in this directory is not an endorsement.